Clinical Trials Transformation Initiative


Clinical Trials Transformation Initiative (CTTI) was established at King Faisal Specialist Hospital & Research Centre late 2021. The establishment stemmed from our legacy as the flagship of excellence in patients’ care and research. The CTTI Division sought to develop and drive adoption of practices that will increase the number, quality, diversity and efficiency of clinical trials. This initiative aspired to position KFSHRC in the forefront as an international hub of choice for clinical trials development and innovation, and most importantly nurturing “hope” to our patients.  We are aligning the national and international efforts in the field of clinical trials with the Saudi 2030 vision.

Through this initiative, KFSHRC instrumenting a structured, time-framed strategy that focuses on enhancing our infrastructure and internal as well as national clinical trials conduction ecosystem, in a patient-centric approach. Through our CITTI platform we are harmonizing the effort between clinical trials executing settings, Research Center, Center of Genomic Medicine, Health Information Technology Affairs, Clinical and Research Lab, other related services, as well as external authorities and industries that impact the conduction of clinical trials in our country. We believe this initiative will improve our patients’ access to new technologies and cutting-edge therapies in addition to improving our infrastructure to adapt to the ever-changing market in the field.

CTTI will achieve its goal through diversified engagement of national and international collaborators that welcome and appreciate our values and share the same vision. CTTI's approach is to involve all sectors in the selection, conduct, and interpretation of its projects; to keep the dialogue open across sectors; to provide evidence that can help our patients.

It worth mentioning that CTTI particularly welcome new cutting-edge therapeutic and diagnostic innovations. This includes the development of advances in gene therapy, cell therapy, stem cell science, regenerative medicine, CRISPR/Cas9 gene editing, and cancer immunotherapy.

KFSHRC will work with our partners and stakeholders to assure world-class, efficient and high-quality conduction of clinical trials. Here is synopsis on selected capacities in our organization.


Internal Stakeholders:

  • Research Center
  • Clinical Research Department
  • Centre for Genomic Medicine (CGM)
  • Department of Pathology and Laboratory Medicine
  • Department of Biostatistics, Epidemiology, and Scientific Computing
  • Pharmaceutical Care Division-Investigational Drug Services
  • Healthcare Information Technology Affairs (HITA)


External Stakeholders:

  • Research, Development, and Innovation Authority (RDIA)-Health
  • Saudi Food and Drug Authority
  • Saudi National Institutes of Health (SNIH)
  • Saudi Authority for Intellectual Property
  • King Abdulaziz City for Science and Technology (KACST)
  • Saudi Health Council (SHC)
  • Saudi Research and Innovation Network (SRIN)